We are live on ! Find out more
IBIO icon

iBio
IBIO

16 hedge funds and large institutions have $3.37M invested in iBio in 2016 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 0 increasing their positions, 2 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

61% more capital invested

Capital invested by funds: $2.1M → $3.37M (+$1.27M)

0% more funds holding

Funds holding: 16 → 16 (0)

0% more ownership

Funds ownership: 0% → 0% (+0%)

0% more first-time investments, than exits

New positions opened: 3 | Existing positions closed: 3

100% less repeat investments, than reductions

Existing positions increased: 0 | Existing positions reduced: 2

Holders
16
Holders Change
–
Holders Change %
0%
% of All Funds
0.43%
Holding in Top 10
1
Holding in Top 10 Change
+1
Holding in Top 10 Change %
% of All Funds
0.03%
New
3
Increased
–
Reduced
2
Closed
3
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
ACP
Arcus Capital Partners
Georgia
+$1.95M
2
JFA
JNBA Financial Advisors
Minnesota
+$97.2K
3
VKH
Virtu KCG Holdings
New York
+$6.27K

Top Sellers

Rank Fund Capital Flow
1
Vanguard Group
Vanguard Group
Pennsylvania
-$28.2K
2
UBS Group
UBS Group
Switzerland
-$22K
3
Millennium Management
Millennium Management
New York
-$7K
4
Bank of New York Mellon
Bank of New York Mellon
New York
-$6.27K
5
Creative Planning
Creative Planning
Kansas
-$2K

IBIO Hedge Fund Activity: Q3 2016 in Review

16 of the 3,759 institutional investors tracked by Wall St. Rank reported a position in iBio (IBIO) for Q3 2016, worth a combined $3.37M — up 61% from $2.1M a quarter earlier.

Fund positioning in IBIO was balanced in Q3 2016: 3 funds opened new positions, 3 closed out, 0 added to existing stakes and 2 trimmed.

The largest buyer was Arcus Capital Partners, opening a new position worth an estimated $1.95M. The largest seller was Vanguard Group, cutting an estimated $28.2K.

  • 16 institutional investors held iBio (IBIO) as of Q3 2016, unchanged from Q2 2016.
  • Funds reported $3.37M of iBio stock for Q3 2016, up 61% quarter-over-quarter.
  • 3 funds opened new iBio positions in Q3 2016 and 3 closed out, a net change of 0 holders.
  • The largest iBio buyer in Q3 2016 was Arcus Capital Partners, an estimated $1.95M added.
  • The largest iBio seller in Q3 2016 was Vanguard Group, an estimated $28.2K sold.

Based on aggregated 13F filings for Q3 2016.